A Phase 2 interventional study of Placebo and Sotatercept in Pulmonary Arterial Hypertension, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Completed at 43 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-19.
Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 2, and was the 1st registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan
Ages 1–17
Kazuya Hosokawa · Sites in Japan
Ages 18+
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18–70
Merck Sharp & Dohme LLC · Sites in United States, Australia, Colombia and 9 more countries
Ages 1–17
By country, each count listing its studies:
sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2018.
This study's enrollment of 106 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 44 across the 18 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, one of the names counted as Merck & Co., Inc. Under that name alone:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc: 3 open now, 5 under way, 1 of them phase 3. Of 12 finished, 11 (92%) have results posted.
Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 6 in phase 2, and was the 4th registered.
Merck & Co., Inc’s Pulmonary Arterial Hypertension studies by the year they started, since 2013.
1 of the studies testing sotatercept in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356778Kazuya HosokawaA Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, from their registry updates:
Among Merck & Co., Inc’s 17 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
Study A011-09 is designed to assesses the efficacy and safety of sotatercept (ACE-011) relative to placebo in adults with pulmonary arterial hypertension (PAH). Eligible participants will receive study treatment for 24 weeks during the placebo-controlled treatment period, and then will be eligible to enroll into a 30-month extension period during which all participants will receive sotatercept. All treated patients will also undergo a follow-up period after last study drug treatment.
This is a Phase 2, double-blind, randomized, placebo-controlled, parallel-group study of sotatercept plus standard of care (SOC) versus placebo plus SOC in participants with PAH of World Health Organization (WHO) Group 1, functional class II-III. Participants will be randomly assigned in a 3:3:4 ratio to receive placebo, sotatercept 0.3 mg/kg, or sotatercept 0.7 mg/kg by subcutaneous (SC) injection every 21 days for a period of 24 weeks in the placebo-controlled treatment period of the study while on SOC therapy. Evaluations will include changes in pulmonary vascular resistance (PVR), 6-minute walk distance (6MWD), quality of life questionnaires, echocardiographic parameters, and safety. Participants who have not discontinued early from the placebo-controlled treatment period and have had their post-treatment period PVR assessment will be able to continue into the 30-month extension period in which sotatercept-treated participants will receive their latest dose level of sotatercept SC every 21 days and placebo-treated participants will be re-randomized 1:1 to receive sotatercept 0.3 mg/kg SC or sotatercept 0.7 mg/kg SC every 21 days while on SOC therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented diagnostic right heart catheterization (RHC) at any time prior to Screening confirming diagnosis of WHO diagnostic pulmonary hypertension Group I: PAH in any of the following subtypes:
i. Idiopathic ii. Heritable PAH iii. Drug- or toxin-induced PAH iv. PAH associated with connective tissue disease v. PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following shunt repair
Pulmonary function tests (PFTs) within 6 months prior to Screening as follows:
Exclusion Criteria:
Any of the following clinical laboratory values during the Screening Period prior to C1D1:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo plus SOC by SC injection during the 24-week treatment period. Dosing will occur once every 3 weeks.
Drug: Placebo · Other: SOC
Participants will receive sotatercept 0.3 mg/kg plus SOC by SC injection during the 24-week treatment period. Per protocol, participants may have their doses titrated. Dosing will occur once every 3 weeks.
Drug: Sotatercept · Other: SOC
Participants will receive sotatercept 0.7 mg/kg plus SOC by SC injection during the 24-week treatment period. Per protocol, participants may have their doses titrated. Dosing will occur once every 3 weeks.
Drug: Sotatercept · Other: SOC
Placebo
Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
Also known as: ACE-011
SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks
Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Extension Period: Change From Baseline in PVR (Delayed-Start Analysis)
Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.
Time frame: Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24
Extension Period: Change From Baseline in PVR (Placebo-Crossed Analysis)
Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.
Time frame: Baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.
Extension Period: Number of Participants Who Experienced One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to approximately 32 months
Extension Period: Number of Participants Who Discontinued Study Treatment Due to an AE
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to 30 months
Base Study: Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks
6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.
Time frame: Baseline and 24 weeks
Base Study: Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks
Each participant's laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were measured at baseline and at 24 weeks.
Time frame: Baseline and 24 Weeks
Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at 24 Weeks
Each participant's TAPSE, which is commonly used to evaluate tricuspid valve annulus movement as an indicator of right heart function, was measured by echocardiography at baseline and 24 weeks.
Time frame: Baseline and 24 weeks
Base Study: Change From Baseline in Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Score at Cycle 9
The CAMPHOR is participant-reported questionnaire that contains 65 items in total, 25 relating to symptoms, 25 relating to quality of life (QoL), and 15 relating to activities. Symptom items are scored from 0-25, with a higher score indicating worse symptoms. QoL items are also scored from 0-25, with a higher score indicating a worse QoL and greater functional limitation. Activity items are scored from 0-30, with a higher score indicating poorer functioning. The combined score is obtained by summing up the symptoms score, QoL score and activity score. The lowest combined score possible is 0, while the highest combined score possible is 80. Each participant's CAMPHOR score was recorded at baseline and on Day 1 of Cycle 9.
Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Base Study: Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score
The SF-36 questionnaire is a participant-reported survey of a participant's health. The survey evaluates 8 aspects of functional health and well-being that relate to either physical health or mental health. The physical component summary is based primarily on physical functioning, bodily pain, and general health. The mental component summary encompasses vitality, social functioning, and emotional and mental health. Total scores for the physical component range from 0-100, with 100 representing the highest level of physical functioning. The total scores for the mental component also range from 0-100, with 100 representing the highest level of mental functioning. Each participant's SF-36 was recorded at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.
Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Base Study: Number of Participants Who Experienced Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH)
Events that indicate clinical worsening of PAH include death, need for and/or worsening-related listing for lung and/or heart transplant, need to initiate an approved PAH SOC rescue therapy, PAH-specific hospitalization, or functional deterioration (worsened WHO Functional Class AND 15% decrease in 6MWD).
Time frame: Up to 24 weeks
Base Study: Number of Participants Who Experienced an Improvement From Baseline in World Health Organization (WHO) Functional Class at 24 Weeks
The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension.
Time frame: Baseline and 24 Weeks
Base Study: Number of Participants Who Experienced One or More AEs
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to 24 weeks
Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to 24 weeks
Base Study: Change From Baseline in Body Mass Index (BMI) at Cycle 9
Each participant's BMI was measured at baseline and at 24 weeks.
Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Base Study: Change From Baseline in Systolic and Diastolic Blood Pressure at Cycle 9
Each participant's systolic and diastolic blood pressure was taken at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.
Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Base Study: Change From Baseline in Respiratory Rate at Cycle 9
Each participant's respiratory rate (number of breaths per minute) was measured at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.
Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Base Study: Change From Baseline in QTcF Interval at Cycle 9
Each participant's QTcF Interval was measured at baseline and on Day 1 of Cycle 9.
Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Base Study: Maximum Plasma Concentration (Cmax) of Sotatercept
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Based on population pharmacokinetic (PopPK) modeling of previous sotatercept studies, Cmax occurs at Day 8 of Cycle 1 after a sotatercept dose is given. The sotatercept concentration at Day 8 of Cycle 1 (each cycle was 21 days) is presented here as Cmax.
Time frame: Day 8 of Cycle 1 (Each cycle was 21 days.)
Extension Period: Change From Baseline in 6MWD (Delayed-Start Analysis)
6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and the timepoint at which the third RCH was performed. This occurred between Month 18 and Month 24, at which time each participant's 6MWD was also measured. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.
Time frame: Baseline and the timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24
Extension Period: Change From Baseline in 6MWD (Placebo-Crossed Analysis)
6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's 6MWD was also measured. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.
Time frame: Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24
Extension Period: Number of Participants Who Experienced an Improvement From Baseline in WHO Functional Class (Delayed-Start Analysis)
The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension. Each participant's WHO Functional Class was assessed at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's WHO Functional Class was also assessed.
Time frame: Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24
Extension Period: Change From Baseline in WHO Functional Class (Placebo-Crossed Analysis)
The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension. Each participant's WHO Functional Class was assessed at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's WHO Functional Class was also assessed.
Time frame: Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24
| Milestone | Extension Period: Placebo→Sotatercept 0.3 mg/kg | Extension Period: Placebo→Sotatercept 0.7 mg/kg | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 32 | 32 | 42 |
| Completed | 0 | 0 | 30 | 31 | 36 |
| Not completed | 0 | 0 | 2 | 1 | 6 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 4 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 |
| Milestone | Extension Period: Placebo→Sotatercept 0.3 mg/kg | Extension Period: Placebo→Sotatercept 0.7 mg/kg | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|---|---|
| Started | 15 | 15 | 0 | 31 | 36 |
| Completed | 13 | 15 | 0 | 28 | 31 |
| Not completed | 2 | 0 | 0 | 3 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Death | 1 | 0 | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Elevated hemoglobin levels | 0 | 0 | 0 | 0 | 1 |
Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and at 24 weeks.
| dynes*sec/cm^5 | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Change from Baseline in PVR at 24 Weeks | -27.6 ± 251.08 | -168.4 ± 262.93 | -258.9 ± 169.42 |
| Baseline | 802.0 ± 331.05 | 772.0 ± 285.62 | 715.5 ± 267.11 |
Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.
| dynes*sec/cm^5 | Placebo-Crossed Treatment Group | Continued Sotatercept Treatment Group |
|---|---|---|
| Extension Period: Change from Baseline in PVR (Delayed-Start Analysis) | -246.9 ± 300.01 | -212.6 ± 254.24 |
| Baseline | 802.0 ± 331.05 | 783.7 ± 371.59 |
Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.
| dynes*sec/cm^5 | Placebo-Crossed Treatment Group |
|---|---|
| Extension Period: Change from Baseline in PVR (Placebo-Crossed Analysis) | -246.9 ± 300.01 |
| Baseline | 802.0 ± 331.05 |
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Participants | Extension Period: Placebo→Sotatercept 0.3 mg/kg | Extension Period: Placebo→Sotatercept 0.7 mg/kg | Extension Period: Sotatercept 0.3 mg/kg | Extension Period: Sotatercept 0.7 mg/kg |
|---|---|---|---|---|
| Extension Period: Number of Participants Who Experienced One or More Adverse Events (AEs) | 14 | 15 | 31 | 36 |
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Participants | Extension Period: Placebo→Sotatercept 0.3 mg/kg | Extension Period: Placebo→Sotatercept 0.7 mg/kg | Extension Period: Sotatercept 0.3 mg/kg | Extension Period: Sotatercept 0.7 mg/kg |
|---|---|---|---|---|
| Extension Period: Number of Participants Who Discontinued Study Treatment Due to an AE | 1 | 0 | 1 | 3 |
6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.
| meters | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks | 31.4 ± 9.69 | 56.0 ± 10.07 | 53.6 ± 9.84 |
Each participant's laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were measured at baseline and at 24 weeks.
| pg/mL | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks | 195.9 ± 726.46 | -718.2 ± 965.12 | -359.0 ± 757.58 |
Each participant's TAPSE, which is commonly used to evaluate tricuspid valve annulus movement as an indicator of right heart function, was measured by echocardiography at baseline and 24 weeks.
| cm | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at 24 Weeks | 0.0 ± 0.39 | 0.1 ± 0.26 | -0.1 ± 0.34 |
The CAMPHOR is participant-reported questionnaire that contains 65 items in total, 25 relating to symptoms, 25 relating to quality of life (QoL), and 15 relating to activities. Symptom items are scored from 0-25, with a higher score indicating worse symptoms. QoL items are also scored from 0-25, with a higher score indicating a worse QoL and greater functional limitation. Activity items are scored from 0-30, with a higher score indicating poorer functioning. The combined score is obtained by summing up the symptoms score, QoL score and activity score. The lowest combined score possible is 0, while the highest combined score possible is 80. Each participant's CAMPHOR score was recorded at baseline and on Day 1 of Cycle 9.
| Score on a scale | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Change From Baseline in Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Score at Cycle 9 | -10.2 ± 12.91 | -6.9 ± 12.51 | -7.5 ± 7.96 |
The SF-36 questionnaire is a participant-reported survey of a participant's health. The survey evaluates 8 aspects of functional health and well-being that relate to either physical health or mental health. The physical component summary is based primarily on physical functioning, bodily pain, and general health. The mental component summary encompasses vitality, social functioning, and emotional and mental health. Total scores for the physical component range from 0-100, with 100 representing the highest level of physical functioning. The total scores for the mental component also range from 0-100, with 100 representing the highest level of mental functioning. Each participant's SF-36 was recorded at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.
| Score on a scale | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Physical component | 3.5 ± 1.07 | 4.5 ± 1.12 | 3.1 ± 1.11 |
| Mental component | 3.2 ± 1.33 | 3.6 ± 1.39 | 0.0 ± 1.40 |
Events that indicate clinical worsening of PAH include death, need for and/or worsening-related listing for lung and/or heart transplant, need to initiate an approved PAH SOC rescue therapy, PAH-specific hospitalization, or functional deterioration (worsened WHO Functional Class AND 15% decrease in 6MWD).
| Participants | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Number of Participants Who Experienced Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH) | 2 | 0 | 1 |
The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension.
| Participants | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Number of Participants Who Experienced an Improvement From Baseline in World Health Organization (WHO) Functional Class at 24 Weeks | 4 | 8 | 6 |
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Participants | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Number of Participants Who Experienced One or More AEs | 29 | 29 | 35 |
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Participants | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE | 1 | 1 | 5 |
Each participant's BMI was measured at baseline and at 24 weeks.
| kg/m^2 | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Change From Baseline in Body Mass Index (BMI) at Cycle 9 | -0.2 ± 1.25 | 0.6 ± 0.89 | 0.2 ± 1.07 |
Each participant's systolic and diastolic blood pressure was taken at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.
| mmHg | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Systolic blood pressure | -0.8 ± 10.06 | 3.4 ± 11.75 | 2.6 ± 12.28 |
| Diastolic blood pressure | 2.3 ± 8.06 | 4.1 ± 8.64 | 1.7 ± 8.69 |
Each participant's respiratory rate (number of breaths per minute) was measured at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.
| breaths/min | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Change From Baseline in Respiratory Rate at Cycle 9 | -0.3 ± 2.10 | -1.3 ± 3.72 | -0.3 ± 3.05 |
Each participant's QTcF Interval was measured at baseline and on Day 1 of Cycle 9.
| milliseconds | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|---|
| Base Study: Change From Baseline in QTcF Interval at Cycle 9 | 0.7 ± 31.10 | -7.4 ± 20.57 | -9.1 ± 31.55 |
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Based on population pharmacokinetic (PopPK) modeling of previous sotatercept studies, Cmax occurs at Day 8 of Cycle 1 after a sotatercept dose is given. The sotatercept concentration at Day 8 of Cycle 1 (each cycle was 21 days) is presented here as Cmax.
| ng/mL | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg |
|---|---|---|
| Base Study: Maximum Plasma Concentration (Cmax) of Sotatercept | 1910.3 ± 715.86 | 4598.5 ± 1622.59 |
6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and the timepoint at which the third RCH was performed. This occurred between Month 18 and Month 24, at which time each participant's 6MWD was also measured. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.
| meters | Placebo-Crossed Treatment Group | Continued Sotatercept Treatment Group |
|---|---|---|
| Extension Period: Change From Baseline in 6MWD (Delayed-Start Analysis) | 60.1 ± 14.35 | 55.7 ± 9.47 |
6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's 6MWD was also measured. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.
| meters | Placebo-Crossed Treatment Group |
|---|---|
| Extension Period: Change From Baseline in 6MWD (Placebo-Crossed Analysis) | 60.5 ± 13.21 |
The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension. Each participant's WHO Functional Class was assessed at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's WHO Functional Class was also assessed.
| Participants | Placebo-Crossed Treatment Group | Continued Sotatercept Treatment Group |
|---|---|---|
| Extension Period: Number of Participants Who Experienced an Improvement From Baseline in WHO Functional Class (Delayed-Start Analysis) | 16 | 27 |
The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension. Each participant's WHO Functional Class was assessed at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's WHO Functional Class was also assessed.
| WHO functional class | Placebo-Crossed Treatment Group |
|---|---|
| Extension Period: Change From Baseline in WHO Functional Class (Placebo-Crossed Analysis) | -0.6 ± 0.74 |
Collected over Treatment period: Up to 24 weeks; Extension period: Up to approximately 32 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Base Study: Placebo | 0/32 (0%) | 3/32 (9.4%) | 25/32 (78.1%) |
| Base Study: Sotatercept 0.3 mg/kg | 0/32 (0%) | 2/32 (6.3%) | 29/32 (90.6%) |
| Base Study: Sotatercept 0.7 mg/kg | 1/42 (2.4%) | 10/42 (23.8%) | 33/42 (78.6%) |
| Extension Period: Placebo→Sotatercept 0.3 mg/kg | 1/15 (6.7%) | 6/15 (40%) | 14/15 (93.3%) |
| Extension Period: Placebo→Sotatercept 0.7 mg/kg | 0/15 (0%) | 4/15 (26.7%) | 15/15 (100%) |
| Extension Period: Sotatercept 0.3 mg/kg | 1/32 (3.1%) | 10/31 (32.3%) | 30/31 (96.8%) |
| Extension Period: Sotatercept 0.7 mg/kg | 2/42 (4.8%) | 12/36 (33.3%) | 36/36 (100%) |
| Event | Base Study: Placebo | Base Study: Sotatercept 0.3 mg/kg | Base Study: Sotatercept 0.7 mg/kg | Extension Period: Placebo→Sotatercept 0.3 mg/kg | Extension Period: Placebo→Sotatercept 0.7 mg/kg | Extension Period: Sotatercept 0.3 mg/kg | Extension Period: Sotatercept 0.7 mg/kg |
|---|---|---|---|---|---|---|---|
| Device malfunctionProduct Issues | 0/32 | 0/32 | 0/42 | 2/15 | 0/15 | 0/31 | 2/36 |
| PneumoniaInfections and infestations | 0/32 | 0/32 | 0/42 | 1/15 | 0/15 | 1/31 | 3/36 |
| Tachycardia paroxysmalCardiac disorders | 0/32 | 0/32 | 0/42 | 1/15 | 0/15 | 0/31 | 0/36 |
| BronchitisInfections and infestations | 0/32 | 0/32 | 1/42 | 1/15 | 0/15 | 0/31 | 0/36 |
| Gastrointestinal infectionInfections and infestations | 0/32 | 0/32 | 0/42 | 1/15 | 0/15 | 0/31 | 0/36 |
| PyelonephritisInfections and infestations | 0/32 | 0/32 | 0/42 | 0/15 | 1/15 | 0/31 | 0/36 |
| Respiratory tract infectionInfections and infestations | 0/32 | 0/32 | 1/42 | 1/15 | 0/15 | 0/31 | 0/36 |
| Ankle fractureInjury, poisoning and procedural complications | 0/32 | 0/32 | 0/42 | 0/15 | 1/15 | 0/31 | 0/36 |
| Colon neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/32 | 0/32 | 0/42 | 1/15 | 0/15 | 0/31 | 0/36 |
| Ischaemic strokeNervous system disorders | 0/32 | 0/32 | 0/42 | 1/15 | 0/15 | 0/31 | 0/36 |
| Event | Base Study: Placebo | Base Study: Sotatercept 0.3 mg/kg | Base Study: Sotatercept 0.7 mg/kg | Extension Period: Placebo→Sotatercept 0.3 mg/kg | Extension Period: Placebo→Sotatercept 0.7 mg/kg | Extension Period: Sotatercept 0.3 mg/kg | Extension Period: Sotatercept 0.7 mg/kg |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 6/32 | 8/32 | 6/42 | 4/15 | 7/15 | 9/31 | 6/36 |
| FatigueGeneral disorders | 6/32 | 2/32 | 4/42 | 6/15 | 4/15 | 6/31 | 5/36 |
| Oedema peripheralGeneral disorders | 5/32 | 3/32 | 5/42 | 4/15 | 6/15 | 11/31 | 7/36 |
| NasopharyngitisInfections and infestations | 3/32 | 1/32 | 4/42 | 5/15 | 6/15 | 10/31 | 1/36 |
| DiarrhoeaGastrointestinal disorders | 5/32 | 7/32 | 6/42 | 3/15 | 5/15 | 9/31 | 5/36 |
| Haemoglobin increasedInvestigations | 0/32 | 1/32 | 7/42 | 1/15 | 5/15 | 0/31 | 5/36 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/32 | 2/32 | 1/42 | 2/15 | 5/15 | 8/31 | 5/36 |
| TelangiectasiaSkin and subcutaneous tissue disorders | 0/32 | 0/32 | 0/42 | 4/15 | 5/15 | 5/31 | 7/36 |
| NauseaGastrointestinal disorders | 5/32 | 3/32 | 5/42 | 3/15 | 4/15 | 9/31 | 5/36 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 2/32 | 1/32 | 0/42 | 0/15 | 4/15 | 1/31 | 3/36 |
| Age, Continuous(Years) | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg | Total |
|---|---|---|---|---|
| Mean | 45.6 ± 13.38 | 49.1 ± 14.34 | 49.8 ± 15.05 | 48.3 ± 14.33 |
| Sex: Female, Male(Participants) | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg | Total |
|---|---|---|---|---|
| Female | 26 | 29 | 37 | 92 |
| Male | 6 | 3 | 5 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 9 | 13 | 32 |
| Not Hispanic or Latino | 21 | 19 | 28 | 68 |
| Unknown or Not Reported | 1 | 4 | 1 | 6 |
| Race (NIH/OMB)(Participants) | Placebo | Sotatercept 0.3 mg/kg | Sotatercept 0.7 mg/kg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 1 | 3 | 4 |
| White | 30 | 31 | 37 | 98 |
| More than one race | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2018 to primary completion in Mar 2022, 44 months.
Results were first posted in Apr 2023, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 44 months is above that.
Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept
Pulmonary Arterial Hypertension →
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA →